190 related articles for article (PubMed ID: 34665339)
1. Systemic Therapy for Metastatic Pancreatic Cancer.
Ettrich TJ; Seufferlein T
Curr Treat Options Oncol; 2021 Oct; 22(11):106. PubMed ID: 34665339
[TBL] [Abstract][Full Text] [Related]
2. Clinical Management: Metastatic Disease.
Ko AH
Cancer J; 2017; 23(6):355-361. PubMed ID: 29189332
[TBL] [Abstract][Full Text] [Related]
3. Advancements in the management of pancreatic cancer: 2013.
Saif MW
JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols.
Abendroth A; Noureddine R; Abramczyk M; Paul A; Gerken G; Schmid KW; Markus P; Schumacher B; Wiesweg M; Köhler J; Markus M; Mende B; Dechêne A; Schuler M; Kasper S
J Cancer Res Clin Oncol; 2019 Feb; 145(2):445-455. PubMed ID: 30430229
[TBL] [Abstract][Full Text] [Related]
5. From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer.
Martín AM; Hidalgo M; Alvarez R; Arrazubi V; Martínez-Galán J; Salgado M; Macarulla T; Carrato A
J Cancer; 2018; 9(11):1978-1988. PubMed ID: 29896283
[TBL] [Abstract][Full Text] [Related]
6. Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives.
Lellouche L; Palmieri LJ; Dermine S; Brezault C; Chaussade S; Coriat R
Ther Adv Med Oncol; 2021; 13():17588359211018539. PubMed ID: 34285720
[TBL] [Abstract][Full Text] [Related]
7. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
Chiang NJ; Chang JY; Shan YS; Chen LT
Expert Opin Pharmacother; 2016 Jul; 17(10):1413-20. PubMed ID: 27140876
[TBL] [Abstract][Full Text] [Related]
8. Treatment Approach to Adenocarcinoma of the Ampulla of Vater.
Patel M; Uboha NV
Curr Treat Options Oncol; 2021 Sep; 22(11):103. PubMed ID: 34586537
[TBL] [Abstract][Full Text] [Related]
9. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Sohal DP; Mangu PB; Khorana AA; Shah MA; Philip PA; O'Reilly EM; Uronis HE; Ramanathan RK; Crane CH; Engebretson A; Ruggiero JT; Copur MS; Lau M; Urba S; Laheru D
J Clin Oncol; 2016 Aug; 34(23):2784-96. PubMed ID: 27247222
[TBL] [Abstract][Full Text] [Related]
10. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
Karzai F; VanderWeele D; Madan RA; Owens H; Cordes LM; Hankin A; Couvillon A; Nichols E; Bilusic M; Beshiri ML; Kelly K; Krishnasamy V; Lee S; Lee MJ; Yuno A; Trepel JB; Merino MJ; Dittamore R; Marté J; Donahue RN; Schlom J; Killian KJ; Meltzer PS; Steinberg SM; Gulley JL; Lee JM; Dahut WL
J Immunother Cancer; 2018 Dec; 6(1):141. PubMed ID: 30514390
[TBL] [Abstract][Full Text] [Related]
11. Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review.
Garcia G; Odaimi M
J Gastrointest Cancer; 2017 Jun; 48(2):121-128. PubMed ID: 28303435
[TBL] [Abstract][Full Text] [Related]
12. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
Li CH; Karantza V; Aktan G; Lala M
Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
[TBL] [Abstract][Full Text] [Related]
13. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
14. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
[TBL] [Abstract][Full Text] [Related]
15. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
[TBL] [Abstract][Full Text] [Related]
16. Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country.
Zahir MN; Jabbar AA
Asian Pac J Cancer Prev; 2015; 16(14):6001-6. PubMed ID: 26320487
[TBL] [Abstract][Full Text] [Related]
17. Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer.
Kieler M; Unseld M; Bianconi D; Prager GW
Memo; 2017; 10(3):136-140. PubMed ID: 28989542
[TBL] [Abstract][Full Text] [Related]
18. Defining and Treating Borderline Resectable Pancreatic Cancer.
Perri G; Prakash L; Katz MHG
Curr Treat Options Oncol; 2020 Jul; 21(9):71. PubMed ID: 32725270
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials.
Huynh J; Patel K; Gong J; Cho M; Malla M; Parikh A; Klempner S
Curr Treat Options Oncol; 2021 Sep; 22(11):100. PubMed ID: 34524553
[TBL] [Abstract][Full Text] [Related]
20. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
